These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 11377521

  • 81. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
    Forsythe J.
    Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
    [No Abstract] [Full Text] [Related]

  • 82. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group.
    Miller J, Pirsch JD, Deierhoi M, Vincenti F, Filo RS.
    Transplant Proc; 1997 Nov; 29(1-2):304-5. PubMed ID: 9123008
    [No Abstract] [Full Text] [Related]

  • 83. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study.
    Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group.
    Lancet; 2002 Mar 02; 359(9308):741-6. PubMed ID: 11888584
    [Abstract] [Full Text] [Related]

  • 84. FK 506 primary immunosuppression following emergency liver transplantation for fulminant hepatic failure. European FK 506 Study Liver Group.
    Devlin J, Wong P, Williams R, Neuhaus P, McMaster P, Calne R, Pichlmayr R, Otto G, Bismuth H, Groth C.
    Transpl Int; 1994 Mar 02; 7 Suppl 1():S64-9. PubMed ID: 11271328
    [Abstract] [Full Text] [Related]

  • 85. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
    Bismuth H.
    Transplant Proc; 1995 Feb 02; 27(1):45-9. PubMed ID: 7533415
    [No Abstract] [Full Text] [Related]

  • 86.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 87.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 88.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 89. Acute rejection and the therapeutic choice of drug.
    Ichikawa Y, Nojima M, Kyo M, Yazawa K, Hanafusa T, Ebisui C, Tsubakihara Y, Fukunishi T, Nagano S.
    Transplant Proc; 2000 Nov 02; 32(7):1759-60. PubMed ID: 11119923
    [No Abstract] [Full Text] [Related]

  • 90.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 91. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal.
    Cronin DC, Bruce DS, Newell KA, Josephson MA, Millis JM, Piper JB, Ruebe M, Kirby M, Thistlethwaite JR, Woodle ES.
    Transplant Proc; 1997 Nov 02; 29(1-2):307. PubMed ID: 9123010
    [No Abstract] [Full Text] [Related]

  • 92. Outcome of monoclonal antibody induction and anti-rejection therapy in pancreas transplantation.
    Bruce DS, Newell KA, Woodle ES, Millis JM, Piper JB, Huss E, Thistlethwaite JR.
    Transplant Proc; 1996 Aug 02; 28(4):2136-7. PubMed ID: 8769180
    [No Abstract] [Full Text] [Related]

  • 93. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience.
    Pham SM, Kormos RL, Kawai A, Murali S, Hattler BG, Demetris AJ, Griffith BP.
    Transplant Proc; 1996 Apr 02; 28(2):1002-4. PubMed ID: 8623208
    [No Abstract] [Full Text] [Related]

  • 94. Complications in immunosuppressive therapy of liver transplant recipients.
    Gruttadauria S, di Francesco F, Pagano D, Vizzini G, Cintorino D, Spada M, Tuzzolino F, Gridelli B.
    J Surg Res; 2011 Jun 01; 168(1):e137-42. PubMed ID: 21074788
    [Abstract] [Full Text] [Related]

  • 95. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations.
    Jain A, Kashyap R, Kramer D, Dodson F, Hamad I, Starzl TE, Fung JJ.
    Transplant Proc; 2001 Jun 01; 33(1-2):1342-4. PubMed ID: 11267319
    [No Abstract] [Full Text] [Related]

  • 96.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 97. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY, Liu YL, Wong KM, Chan HW, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Shek CC, Li CS.
    Nephrology (Carlton); 2008 Jun 01; 13(3):251-5. PubMed ID: 18221256
    [Abstract] [Full Text] [Related]

  • 98. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis.
    Kumar MS, Cahill K, Kumar AM, Panigrahi D, Seirka D, Singleton R, al-Abdullah IH, Laskow DA.
    Transplant Proc; 1998 Jun 01; 30(4):1351-2. PubMed ID: 9636549
    [No Abstract] [Full Text] [Related]

  • 99. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation.
    Langrehr JM, Klupp J, Pfitzmann R, Neumann U, Lohmann R, Jonas S, Neuhaus R, Steinmüller T, Neuhaus P.
    Transplant Proc; 2001 Jun 01; 33(1-2):1520. PubMed ID: 11267404
    [No Abstract] [Full Text] [Related]

  • 100. Metabolic findings after liver transplantation within a randomised trial with or without steroids.
    Tisone G, Angelico M, Vennarecci G, Palmieri G, Buonomo O, Negrini S, Casciani CU.
    Transplant Proc; 1998 Jun 01; 30(4):1447-8. PubMed ID: 9636587
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.